It is widely believed that HCC patients with elevated KLF4 levels are more susceptible to immune checkpoint blockades (ICBs) and that targeting KLF4 could affect exhausted T cell reprogramming to improve immune responses to cancer cells. This evidence concerns the gene KLF4 and hepatocellular carcinoma.